Heron Therapeutics opened higher at $0.36, compared with its previous close of $0.36. In the last trading session, the stock traded between $0.32 and $0.36. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Heron Therapeutics is now worth
$ 2.91
Resulting in a loss of
$ 97.09 (97.09%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.03 (-8.15%)
Day High
$0.36
Day Low
$0.32
Day Open
$0.36
Prev Close
$0.36
Volume
67,82,899
1W Return
11.11%
1M Return
-21.05%
3M Return
2.48%
6M Return
-65.46%
1Y Return
-71.55%
Fundamentals
Market Cap ($ Mn)
63
PE Ratio
-
PB Ratio
10.56
PEG Ratio
-
ROE
-
ROCE
-10.78%
EPS (TTM)
$-0.03
Investment Returns
1 Week
11.11%
1 Month
-21.05%
3 Months
2.48%
6 Months
-65.46%
9 Months
-71.79%
Financials
Quarterly
All values in $ Mn
38.2
Sep 25
40.6
Dec 25
0.0
Mar 26
34.7
Mar 26
37.7
Jun 26
35.3
Sep 26
Updates
9Nov
Heron Therapeutics Q3 loss narrows; CorMedix to acquire assets
Heron Therapeutics reported Q3 sales of $35.25 million, missing estimates by 6%. Net loss narrowed to $(0.03) per share, meeting analyst consensus. CorMedix Therapeutics agreed to acquire substantially all of Heron's assets. Acute Care revenue rose 22.5% YoY, offsetting a 22.2% decline in Oncology.
3 days ago
30Sep
Heron Therapeutics secures exclusive US license for Long Grove products
Heron Therapeutics entered a multi-product development and license agreement with Long Grove Pharmaceuticals on September 23, 2026. The deal grants Heron an exclusive, sublicensable license to market products in the United States and its territories. Heron holds a non-exclusive worldwide manufacturing license for products sold in the defined Territory. Financial terms include regulatory milestones, sales-based milestones, royalties, and expense reimbursements. Capstone Development Services Company is a party solely for exclusivity covenants and backstop obligations.
